TAO Synergies (TAOX) Change in Accured Expenses (2019 - 2026)
TAO Synergies' (TAOX) quarterly Change in Accured Expenses came in at -$24972.0 in Q2 2026, up 17.8% on a YoY basis from -$21198.4 in Q2 2025, and up 94.81% quarter-over-quarter from -$481100.0 in Q1 2026.
Analysis
TAO Synergies (TAOX) Change in Accured Expenses (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Change in Accured Expenses for 8 consecutive years, with -$24972.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Accured Expenses rose 17.8% year-over-year to -$24972.0; the trailing twelve-month figure through Jun 2026 stood at $66340.0 (up 256.99% YoY), and the FY2025 full-year result was -$58464.0, down 122.39% from the prior year.
- Change in Accured Expenses rose to -$24972.0 in Q2 2026 per TAOX's latest filing, from -$481100.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $642438.0 in Q4 2024 and bottomed at -$600496.0 in Q1 2025.
- Historically, Change in Accured Expenses has averaged -$31442.3 across 5 years, with a median of $2030.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses slumped 17589.87% in 2024, then jumped 274.48% in 2025.
- Over 5 years, Change in Accured Expenses stood at $336509.0 in 2022, then gained by 6.79% to $359348.0 in 2023, then jumped by 78.78% to $642438.0 in 2024, then slipped by 14.99% to $546120.0 in 2025, then plunged by 104.57% to -$24972.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$24972.0, -$481100.0, and $546120.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.88 Bn | 197.89 Bn | 7.24 Bn | 852.00 Mn |
| 2 | Gilead Sciences | 181.55 Bn | 178.37 Bn | 6.22 Bn | 338.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.31 Bn | 124.45 Bn | 2.84 Bn | 222.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.51 Bn | 74.52 Bn | 3.93 Bn | 492.70 Mn |
| 5 | Argenx Se | 61.54 Bn | 56.36 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.69 Bn | 49.55 Bn | 52.00 Mn | 11.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.07 Bn | 30.76 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Biogen | 31.41 Bn | 30.12 Bn | 1.96 Bn | -49.70 Mn |
| 9 | Roivant Sciences | 30.10 Bn | 30.10 Bn | 1.16 Mn | -13.91 Mn |
| 10 | TAO Synergies | 30.93 Mn | 30.93 Mn | - | -24,972.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24,972.00 |
| Mar 31, 2026 | -481,100.00 |
| Dec 31, 2025 | 546,120.00 |
| Sep 30, 2025 | 26,292.00 |
| Jun 30, 2025 | -30,380.00 |
| Mar 31, 2025 | -600,496.00 |
| Dec 31, 2024 | 642,438.00 |
| Sep 30, 2024 | 7,021.00 |
| Jun 30, 2024 | 1,829.00 |
| Mar 31, 2024 | -390,199.00 |
| Dec 31, 2023 | 359,348.00 |
| Sep 30, 2023 | 8,406.00 |
| Jun 30, 2023 | -470,808.00 |
| Mar 31, 2023 | 2,231.00 |
| Dec 31, 2022 | 336,509.00 |
| Sep 30, 2022 | -144,909.00 |
| Jun 30, 2022 | 77,125.00 |
| Mar 31, 2022 | -430,417.00 |
| Dec 31, 2021 | 626,450.00 |
| Sep 30, 2021 | -49,855.00 |